Central nervous system disorders, including dementia and neurodegenerative diseases, are becoming major medical and societal challenges worldwide as global aging progresses.
In recent years, research on blood-based biomarkers, which use ultra‑trace molecules in blood as indicators, has advanced rapidly.
Technologies that detect early signs of disease from blood hold significant potential in research, drug discovery, and future diagnostic applications.
However, the ability to measure and the ability to measure consistently and reliably are fundamentally different.
Unless the barriers of reproducibility, quantification, and standardization are overcome, research findings cannot be translated into real-world implementation.
 

Our blood biomarker business is not simply about developing instruments.
Our goal is to build a comprehensive measurement platform for blood-based biomarkers.
The fully automated ELISA system “KI‑ZA‑SHI” serves as the core measurement foundation.
Key features include:

• Automation of measurement processes
• Reduction of human‑induced variability
• Capability to detect ultra‑trace analytes
• Design optimized for continuous operation
   

By combining instrument installation with dedicated reagents, operational expertise, and expansion of measurable biomarkers, we transform measurement from a one‑off experiment into a sustainable, scalable system.
This is the essence of our platform strategy.
 

Many biological technologies demonstrate promising results in research settings but face barriers to industrialization due to challenges in reproducibility and quality control.
Leveraging our expertise in the semiconductor and precision equipment industries—
 

• Automation technologies
• Precision control engineering
• Quality‑stabilization know‑how
• Mass‑production design capabilities

—we aim to elevate biological research outcomes into industrial‑grade infrastructure.
Our blood biomarker business represents a strategic domain that integrates biotechnology with advanced instrumentation.
 

This business is built on a platform‑based model in which value accumulates through system operation and continuous expansion, beginning with the installation of the instrument. 
As the system operates, the ongoing use of dedicated reagents and consumables generates recurring value, while the expansion of measurable biomarkers further increases the value of each installed unit.

This represents a shift from one‑time instrument sales to a continuous and expandable revenue structure. We position this business as a long‑term growth driver that enhances corporate value through sustained operation and platform expansion, rather than short‑term device deployment alone.

We are currently in the phase of system deployment and market penetration.
As installation records accumulate and system utilization becomes visible, the platform’s value will emerge progressively.
Future growth drivers include:
 

• Expansion of measurable biomarkers
• Advancement of operational sophistication
• Utilization and scalability of accumulated data

Through these initiatives, we aim to develop the blood biomarker business into a robust, long‑term growth foundation.

Our ambition is not to limit blood‑based biomarker measurement to a small segment of research.
We aim to build a reliable, reproducible, and stable measurement platform that supports progress in research, drug discovery, and healthcare.
The blood biomarker business is a core strategic initiative for our company—one that unites societal value with long‑term business strategy.